Stock VRDN VIRIDIAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Viridian Therapeutics, Inc.

Equities

VRDN

US92790C1045

Delayed Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
12.11 USD -0.41% Intraday chart for Viridian Therapeutics, Inc. -9.96% -44.40%
May. 16 Transcript : Viridian Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 04:35 PM
May. 09 Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Transcript : Viridian Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 04:35 PM
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
AQ
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
BU
Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating
MT
B. Riley Downgrades Viridian Therapeutics to Neutral From Buy
MT
B. Riley Downgrades Viridian Therapeutics to Neutral From Buy, Cuts Price Target to $20 From $25
MT
Wedbush Raises Viridian Therapeutics Price Target to $42 From $40, Maintains Outperform Rating
MT
Earnings Flash (VRDN) VIRIDIAN THERAPEUTICS Reports Q1 Revenue $72,000
MT
Transcript : Viridian Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024
Viridian Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
BU
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
BU
Foghorn Therapeutics Names Kristian Humer CFO
MT
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
VIRIDIAN Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm
PR
B. Riley Lowers Viridian Therapeutics' PT to $25 From $29, Keeps Buy Rating; Adjusts Model to Reflect Recent Equity Offering, Quarterly Numbers
MT
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VRDN Stock
  4. News Viridian Therapeutics, Inc.